StockData

Atara Biotherapeutics vs TScan Therapeutics

ATRA and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ATRA and TCRX compare

Atara Biotherapeutics is the larger company, worth 6.4 times as much as TScan Therapeutics ($65.2M against $10.2M).

TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −96.7% for Atara Biotherapeutics).

Atara Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −269% compared with −1655% at TScan Therapeutics.

TScan Therapeutics scores higher on the StockData Score (4 against 3 for Atara Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricATRATCRX
Size and price
Market cap$65.2M$10.2M
Share price$6.50$0.151
Change, 1 year−52.8%−86.3%
Change, 5 years−98.5%−98.3%
Beta (5Y)1.992.15
Employees14142
StockData Score
Total score34 (better)
Valuation score03 (better)
Growth score1 (better)0
Performance score1 (better)0
Health score11
Dividend score00
Valuation
P/S10.5×1.4× (better)
P/B–0.1×
FCF yield–−1157%
Fair value–$1.36
Margin of safety–88.9%
Growth
Revenue growth (TTM)−96.7%2.2% (better)
Revenue growth, 5Y average–56.9%
Net income growth (TTM)−388%–
Profitability
Operating margin−230% (better)−1695%
Net margin−269% (better)−1655%
FCF margin–−1666%
Return on equity–−95.8%
Financial health
Debt / equity–0.47
Interest coverage−5.0× (better)−43.2×
Current ratio1.983.37 (better)
Altman Z-score−136.12−6.31 (better)
Piotroski F-score5 (better)2
Dividends and buybacks
Buyback yield−14.2%–
Shareholder yield−14.2%0.00% (better)
Ownership
Held by institutions44.5%53.5%
Held by insiders55.5%32.8%
Insider net buying, 12 months$2.0M (better)$146K
Short interest, % of float6.6%4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.